Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 6/20 | 0.47 |
| ▸ | MC4R | P32245 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5227425 | 1.00 | CTSC (0.47) | CTSCMC4RDPP4HTR2CHTR2B | |
| SCHEMBL7067405 | 0.88 | CTSC (0.59) | CTSCMC4RDPP4HTR2CHTR2B | |
| SCHEMBL18556183 | 0.88 | CTSC (0.59) | CTSCMC4RDPP4HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL18546507 | 0.86 | CTSC (0.58) | CTSCMC4RDPP4HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL18554365 | 0.86 | CTSC (0.58) | CTSCMC4RDPP4HTR2CHTR2B | |
| SCHEMBL20811542 | 0.83 | KCNH2 (0.51) | CTSCMC4RHTR2C | |
| SCHEMBL30524906 | 0.83 | KCNH2 (0.51) | CTSCMC4RHTR2C | |
| Trifluoroacetic Acid SCHEMBL22206760 | 0.82 | MC4R (0.49) | CTSCMC4RHTR2CEPHX2 | |
| SCHEMBL18554335 | 0.76 | CTSC (0.58) | CTSCMC4RDPP4EPHX2 | |
| SCHEMBL17346737 | 0.75 | MTOR (0.44) | CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406872-B1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK & CO INC (US) | 2007-12-19 | — | — | EP | disclosed |
| US-7098239-B2 | Dipeptidyl peptidase inhibitors for the treatment of diabetes | MERCK & CO., INC (US) | 2006-08-29 | — | — | US | disclosed |
| US-20040176428-A1 | Dipeptidyl peptidase inhibitors for the treatment of diabetes | MERCK SHARP & DOHME CORP. | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176428-A1 | Dipeptidyl peptidase inhibitors for the treatment of diabetes | DPP4, DPP3, DPP9 | CTSC 10/4885MC4R 444/4885DPP4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.